CC-AVI401-017XLSX
Source excerpt · Change!A1:C9
Havenor Therapeutics · Its newest medicine, Avericin, is finished and waiting for a health authority to approve it.
Task 02 · Head of CMC and MSAT
State the technical position on the alternate overwrap change
Give the engineering team’s position on what the proposed wrapper means for what was filed with the regulator.
GPT-5.6 Sol caught 7 of 11 traps. See which →
3What just happened?
A film supplier has proposed replacing the outer wrapper on Avericin’s bags.
The wrapper keeps oxygen away from the medicine. Because Avericin is under review, any change to its packaging may have to be reported to the regulator. The regulatory team wants the engineers’ view first.
4Who has to do what?
Give the engineering team’s position on what the proposed wrapper means for what was filed with the regulator.
- The seat
- Jae Calder, Head of CMC and MSAT
- What a good answer looks like
- It keeps “proposed” and “approved” apart, compares the films on the property that matters (oxygen), and shows why a weaker barrier hits exactly the impurity that already limits shelf life.
- What must be handed in
CC-AVI401-017_CMC_regulatory_impact_brief.docx
The assignment as the model received it
Distinguish the proposed alternate overwrap from the registered barrier system and state the evidence and decisions still required.
5Which files decide it?
The supplier’s letter with its comparison table, the engineers’ draft assessment, the change status sheet, and the shelf-life data.
The model also has the rest of the company’s shared drive, its chat and its record systems. Finding the right files is part of the job. Flip through the key ones below.
Company documents
Some of the documents available to the model.
Change control · workbook
A change waiting for approval
The proposed film already has a material ID. This workbook shows how far the change has actually progressed.
The proposed material exists in the record. Quality approval has not been requested, and implementation is not authorized.
1 / 3
6What did the model do?
What GPT-5.6 Sol did, step by step.
In short: Sol compares the two films’ barriers, projects the worst lot’s impurity level at 36 months, and checks the rendered brief page by page.
Step 13. Projects the worst lot to 36 months. Sol’s own regression puts the 250 mL lot at 0.636% at 36 months, above the 0.50% limit. The brief does not connect this to the change: a weaker oxygen barrier acts on the impurity that already limits shelf life.
Calculation resultR03 int 0.06685714285714286 slope 0.015809523809523808 24 0.4462857142857143 36 0.6359999999999999
Bears on: Shelf life is already tight
Step 15. Weighs the two films. Sol notes that the water-vapour advantage does not offset the weaker oxygen barrier. It takes both films’ figures from the proposing supplier’s letter without tracing where the incumbent film’s figure came from.
Text written into the briefHF-55 is ~20% lower for WVTR; this does not offset oxygen risk.
Bears on: The supplier graded its own homework
Step 18. Checks its own rendered pages. Before finishing, Sol renders the brief to images and inspects the pages for layout problems.
File opened by the model/tmp/pages/p-5.png
Replay every step of the run →
Inside the run
A
Model
Projects the worst lot to 36 months
Tool result
R03 int 0.06685714285714286 slope 0.015809523809523808 24 0.4462857142857143 36 0.6359999999999999
A
Sol’s own regression puts the 250 mL lot at 0.636% at 36 months, above the 0.50% limit. The brief does not connect this to the change: a weaker oxygen barrier acts on the impurity that already limits shelf life.
1 / 3
7Which traps did it catch?
It caught 7 of 11.
Specialists wrote these checks from the real records before any model ran. Each is a weak spot a reviewer or inspector would find. A check passes only if the handed-in file states it.
Missed
Proposed is not approved R01
The current wrapper film is the approved one. The new film is only proposed: on hold, not approved by Quality, not assessed by Regulatory, not authorized.
If missed, a proposal gets treated as a done deal.
Old test results don’t cover the new film R08
The existing filter and container tests were done with the current wrapper. Whether they apply to the new film still has to be reviewed.
If missed, the new wrapper would be treated as tested when it never was.
The supplier graded its own homework R09
The “new film is as good as the old one” comparison uses the new supplier’s numbers for both films. Nothing from the current supplier confirms the old film’s figure.
If missed, a weaker oxygen barrier could get through, and the medicine could break down before its expiry date.
Shelf life is already tight R11
The data already point to about 24 months against a 36-month claim. A film that lets in more oxygen acts on the very impurity that is setting that limit.
If missed, the riskiest possible change is handled like a routine one.
Caught
The new film lets in more oxygen R02
At both reported conditions the new film lets through more oxygen: 2.1 vs 0.8, and 3.8 vs 2.4.
If missed, a weaker barrier is accepted as equal.
Oxygen is what matters here R03
The impurity that limits shelf life forms when the medicine reacts with oxygen, so the new film’s better moisture barrier doesn’t make up for its worse oxygen barrier.
If missed, the films are compared on the wrong property.
Measured at the wrong temperature R04
The supplier measured at 23 °C, not at the 25 °C / 60% humidity storage condition.
If missed, the comparison is stretched beyond what was actually measured.
The wrapper is part of the shelf-life evidence R05
The ongoing shelf-life study assumes the current wrapper. A weaker film needs new bridging tests before it can be used.
If missed, the shelf-life claim loses its support.
The sealing heat was never tried here R06
The supplier suggests a sealing temperature, but it has never run Havenor’s machines and there is no Havenor setting to compare against.
If missed, badly sealed wrappers could let oxygen in.
A letter and a draft prove nothing yet R07
The supplier’s notification is just a letter and the assessment is an unapproved draft; neither makes the new film qualified.
If missed, paperwork in progress is treated as proof.
“It fits” is only the supplier’s word R10
The supplier says its film fits the existing bag sizes, but Havenor’s own drawing of the part is still listed as missing.
If missed, wrappers that don’t fit could reach the packing line.
Every model on the same job
One attempt each, same assignment and checklist, so treat small gaps as noise.
Submitted document
CC-AVI401-017_CMC_regulatory_impact_brief.docx
1 / 7
Talk to usRequest the full Biopharma Bench V0.1 — company environments and run receipts: team@raycaster.ai